Effectiveness and safety of lidocaine use (review)
https://doi.org/10.15372/SSMJ20200602
Abstract
Cardiac arrhythmias are complications of many cardiovascular diseases. They quite often acquire an unpredictable course and can result in the death. According to epidemiology data, heart rhythm disorders lead to the sudden death of about 200 thousand people in the Russian Federation annually. Sudden cardiac death overtakes about 400 thousand outpatients and hospital patients in the USA and about 280 thousand patients in Europe. The unpredictability of the occurrence and the transience of cardiac arrhythmias require urgent measures, including both non-pharmacological (electrical pacing, electrical shock therapy) and pharmacotherapeutic methods of treatment. This review is devoted to the study of the clinical features of the lidocaine infusions in patients with ventricular arrhythmias caused by an increase of the conducting cardiomyocytes automatism. The article presents the results of comparative effectiveness and safety studies of lidocaine prescribed for the treatment of ventricular tachycardia and ventricular fibrillation (in the absence of the effect of electro-impulse therapy). Lidocaine is compared with other antiarrhythmic drugs such as amiodarone, sotalol, bretylium tosylate and procainamide. Recommendations of ILCOR (International Committee for Interaction in the Field of Resuscitation), AHA (American Cardiology Association), ECS (European Cardiology Society) and European Society for Resuscitation for the treatment of refractory forms of ventricular arrhythmias and ventricular fibrillation are also discussed.
About the Authors
A. V. Matveev
National Scientific Center of Pharmacovigilance; Medical Academy n.a. S.I. Georgievsky, Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Aleksandr V. Matveev - candidate of medical sciences.
127051, Moscow, Malaya Sukharevskaya sq., 2, bldg. 2; 295051, Simferopol, Lenina blvd., 5/7
A. E. Krasheninnikov
National Scientific Center of Pharmacovigilance
Russian Federation
Russian Federation
Anatoliy Ye. Krasheninnikov - candidate of pharmaceutical sciences.
127051, Moscow, Malaya Sukharevskaya sq., 2, bldg. 2
E. A. Egorova
Medical Academy n.a. S.I. Georgievsky, Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Elena A. Egorova - candidate of pharmaceutical sciences.
295051, Simferopol, Lenina blvd., 5/7
E. A. Matveeva
Medical Academy n.a. S.I. Georgievsky, Crimean Federal University n.a. V.I. Vernadsky
Russian Federation
Russian Federation
Elena A. Matveeva
295051, Simferopol, Lenina blvd., 5/7
References
1. Dumanskii Yu.V., Kabanova N.V., Verkhulet-skii I.E., Sinepupov N.A., Osipov A.G., Sinepupov D.N. Acute circulatory disorders. Meditsina neotlozhnykh sostoyanii = Emergency Medicine. 2012; (2): 71-87. [In Russian].
2. Shul’man V.A., Nikulina S.Yu., Kuzhel’ D.A., Matyushin G.V. Primary arrhythmias:a training manual. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2009; (1): 51-52. [In Russian].
3. Koster R.W., Walker R.G., Chapman F.W. Recurrent ventricular fibrillation during advanced life support care of patients with prehospital cardiac arrest. Resuscitation. 2008; 78 (3): 252-257. doi: 10.1016/j.resuscitation.2008.03.231
4. Link M.S., Berkow L.C., Kudenchuk P.J., Halperin H.R., Hess E.P., Moitra V.K., Neumar R.W., O’Neil B.J., Paxton J.H., Silvers S.M., White R.D., Yannopoulos D., Donnino M.W. Part 7: Adult advanced cardiovascular life support. Circulation. 2015; 132 (18): 444-464. doi: 10.1161/CIR.0000000000000261
5. McLeod S.L., Brignardello-Petersen R., Wor-ster A., You J., Iansavichene A., Guyatt G., Cheskes S. Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis. Resuscitation. 2017; 121: 90-97. doi: 10.1016/j.resuscitation.2017.10.012
6. Soar J., Nolan J.P., Bottiger B.W., Perkins G.D., Lott G., Carli P., Pellis T., Sandroni C., Skrifvars M.B., Smith G.B., Sunde K., Deakin Ch.D., Adult advanced life support section Collaborators. European resuscitation council guidelines for resuscitation 2015. Section 3. Adult advanced life support. Resuscitation. 2015; 95: 100-147. doi: 10.1016/j.resuscitation.2015.07.016
7. White R.D., Russell J.K. Refibrillation, resuscitation and survival in out-of-hospital sudden cardiac arrest victims treated with biphasic automated external defibrillators. Resuscitation. 2002; 55 (1): 17-23. doi: 10.1016/S0300-9572(02)00194-6
8. Bunin Yu.A. Treatment for cardiac arrhythmias in pregnancy:efficiency and safety. Cardiosomatika = Cardiosomatics. 2013; 2 (4): 81-91. [In Russian].
9. Harrison E.E. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann. Emerg. Med. 1981; 10 (8): 420-423. doi: 10.1016/S0196-0644(81)80309-5
10. Herlitz J., Ekstrom L., Wennerblom B., Axelsson A., Bang A., Lindkvist J., Persson N.G., Holmberg S. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997; 33 (3): 199-205. doi: 10.1016/S0300-9572(96)01018-0
11. Kudenchuk P.J., Brown S.P., Daya M., Rea T., Nichol G., Morrison L.J., Leroux B., Vaillancourt C., Wittwer L., Callaway C.W., Christenson J., Egan D., Ornato J.P., Weisfeldt M.L., Stiell I.G., Idris A.H., Auf-derheide To.P., Dunford J.V., Colella R.M., Vilke G.M., Brienza A.M., Desvigne-Nickens P., Gray P.C., Gray R., Seals N., Straight R., Dorian P. Resuscitation outcomes consortium investigators. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N. Engl. J. Med. 2016; 374: 1711-1722. doi: 10.1056/NEJMoa1514204
12. Kudenchuk P.J., Leroux B.G., Daya M., Rea T., Vaillancourt C., Morrison L.J., Callaway C.W., Christenson J., Ornato J.P., Dunford J.V., Wittwer L., Weisfeldt M.L., Aufderheide T.P., Vilke G.M., Idris A.H., Stiell I.G., Colella M.R., Kayea T., Egan D.A., Desvigne-Nickens P., Gray P., Gray R., Straight R., Dorian P. and the Resuscitation outcomes consortium investigators. Antiarrhythmic drugs for non-shockable-turned-shockable out-of-hospital cardiac arrest: The amiodarone, lidocaine or placebo study (ALPS). Circulation. 2017; 136 (22): 2119-2131. doi:10.1161/circulationaha.117.028624
13. Huang C.H., Yu P.H., Tsai M.S., Chuang P.Y., Wang T.D., Chiang C.Y., Chang W.Ti., Ma M.H.M., Tang C.H., Chen W.J. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: A nationwide cohort study. Int. J. Cardiol. 2017; 227: 292-298. doi: 10.1016/j.ijcard.2016.11.101
14. Valdes S.O., Donoghue A.J., Hoyme D.B., Hammond R., Berg M.D., Berg R.A., Samson R.A. American heart association get with the guidelines-resuscitation investigators. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation. 2014; 85 (3): 381-386. doi: 10.1016/j.resuscitation.2013.12.008
15. Gaisenok O.V. The use of amiodarone in clinical practice: the problem of side effects. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2010; 6 (6): 823-827. [In Russian].
16. Dorian P., Cass D., Schwartz B., Cooper R., Gelaznikas R., Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med. 2002; 346 (12): 884-890. doi: 10.1056/NEJMoa013029
17. Rea R.S., Kane-Gill S.L., Rudis M.I., Sey-bert A.L., Oyen L.J., Ou N.N, Stauss J.L., Kirisci L., Idrees U., Henderso S.O. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. Crit. Care Med. 2006; 34 (6): 1617-1623. doi: 10.1097/01.CCM.0000217965.30554.D8
18. Tagami T., Matsui H., Tanaka C., Kaneko J., Kuno M., Ishinokami S., Unemoto K., Fushimi K., Yasunaga H. Amiodarone compared with lidocaine for out-of-hospital cardiac arrest with refractory ventricular fibrillation on hospital arrival: a nationwide database study. Cardiovasc. Drugs Ther. 2016; 30 (5): 485-491. doi: 10.1007/s10557-016-6689-7
19. Pollak P.T., Wee V., Al-Hazmi A., Martin J., Zarnke K.B. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. Can. J. Cardiol. 2006; 22 (3): 199-202. doi: 10.1016/s0828-282x(06)70896-0
20. Volkov V.E. Possibilities of rational use of sotalol in cardiology. Atmosfera. Novosti kardiologii = Atmosphere. Cardiology News. 2009; (1): 22-24. [In Russian].
21. Ho D.S., Zecchin R.P., Richards D.A., Uther J.B., Ross D.L. Double-blind trial of lignocaine versus so-talol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994; 344 (8914): 1823. doi: 10.1016/s0140-6736(94)91048-0
22. Kovoor P., Love A., Hall J., Kruit R., Sadick N., Ho D., Adelstein B.A., Ross D.L. Randomized doubleblind trial of sotalol versus lignocaine in out-of-hospi-tal refractory cardiac arrest due to ventricular tachyarrhythmia. Intern. Med. J. 2005; 35 (9): 518-525. doi: 10.1111/j.1445-5994.2005.00896.x
23. Pantazopoulos I.N., Troupis G.T., Pantazopoulos C.N., Xanthos T.T. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J. Cardiol. 2011; 3 (6): 169-176. doi: 10.4330/wjc.v3.i6.169
24. Shiga T., Tanaka K., Kato R., Amino M., Matsudo Y., Honda T., Sagara K., Takahashi A., Katoh T., Urashima M., Ogawa S., Takano T., Kasanuki H. Refractory VT/VF, Prospective evaluation to differentiate lidocaine efficacy from nifekalant (RELIEF) study investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation. 2010; 81 (1): 47-52. doi: 10.1016/j.resuscitation.2009.09.027
25. Tahara Y., Kimura K., Kosuge M., Ebina T., Sumita S., Hibi K., Toyama H., Kosuge T., Moriwaki Y., Suzuki N., Sugiyama M., Umemura S. Comparison of nifekalant and lidocaine for the treatment of shockrefractory ventricular fibrillation. Circ. J. 2006; 70 (4): 442-446. doi: 10.1253/circj.70.442
26. Kulik V.L., Burda I.Yu., Makienko N.V., Vlasenko O.A., Savchenko V.N. The clinical pharmacology of antiarrhythmic drugs class III. VisnykKharkivs'koho natsional'noho universytetu imeni Vasilya Nazarovi-cha Karazina. Seriya «Medytsyna» = The Journal of V.N. Karazin Kharkiv National University. Series «Medicine». 2010; (19): 104-107. [In Russian].
27. Haynes R.E., Chinn T.L., Copass M.K., Cobb L.A. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: A randomized clinical trial. Am. J. Cardiol. 1981; 48 (2): 353-356. doi: 10.1016/0002-9149(81)90619-6
28. Olson D.W., Thompson B.M., Darin J.C., Mil-brath M.H. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann. Emerg. Med. 1984; 13 (9): 807810. doi: 10.1016/s0196-0644(84)80444-8
29. Suvorov M.A., Suvorov A.V., Kaurov Ya.V., Gnelitsky G.I. Treatment of violations of rhythm and conductivity of heart at sharp poisoning of cardiotox-yc substanes. Zdorov’ye i obrazovaniye v XXI veke = Health and Education in the 21st Century. 2013; 15 (14): 232-233. [In Russian].
30. Stiell I.G., Wells G.A., Hebert P.C., Laupa-cis A., Weitzman B.N. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad. Emerg. Med. 1995; 2 (4): 264-273. doi: 10.1111/j.1553-2712.1995.tb03220.x
31. Igarashi M., Fujino T., Toyoda M., Sug-ino K., Sasao K., Sasamoto S., Otsuka T., Kobayashi K., Okano Y., Yosiwara K., Koyama N. Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation. Pacing Clin. Electrophysiol. 2005; 28 (1): 155-157. doi: 10.1111/j.1540-8159.2005.00043.x
32. Chowdhury A., Fernandes B., Melhuish T.M., White L.D. Antiarrhythmics in cardiac arrest: A systematic review and meta-analysis. Heart Lung Circ. 2018; 27 (3): 280-290. doi: 10.1016/j.hlc.2017.07.004
33. Ali M.U., Fitzpatrick-Lewis D., Kenny M., Raina P., Atkins D.L., Soar J., Nolan J., Ristagno G., Sherifali D. Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review. Resuscitation. 2018; 132: 63-72. doi: 10.1016/j.resuscitation.2018.08.025
34. Khan S.U., Winnicka L., Sallem M.A., Rahman H., Rehman N. Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. Heart Lung. 2017; 46 (6): 417-424. doi: 10.1016/j.hrtlng.2017.09.001
35. Suzuki M., Nagahori W., Mizukami A., Matsumura A., Hashimoto Y. A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis. J. Arrhythm. 2016; 32 (3): 186-190. doi: 10.1016/j.joa.2016.01.004
36. Panchal A.R., Berg K.M., Kudenchuk P.J., Rios M.D., Hirsch K.G., Link M.S., Kurz M.C., Chan P.S., Cabanas J.G., Morley P.T., Hazinski M.F., Donnino M.W. 2018 American heart association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: An update to the American heart association guidelines for cardiopulmonary resuscitation and em. Circulation. 2018; 138 (23): 740-749. doi: 10.1161/CIR.0000000000000613
Review
For citations:
Matveev A.V., Krasheninnikov A.E., Egorova E.A., Matveeva E.A. Effectiveness and safety of lidocaine use (review). Сибирский научный медицинский журнал. 2020;40(6):12-22. (In Russ.) https://doi.org/10.15372/SSMJ20200602
Views:
412
Email this article 